Radiopharmaceutical CDMO Market Size, Share, Trends, Growth and Forecast 2034

Radiopharmaceutical CDMO Market

Radiopharmaceutical CDMO Market By Service Type (Contract Manufacturing, Analytical & Quality Control Services, Contract Development and Packaging, Labeling & Logistics), By Radioisotope Type (Fluorine-18, Gallium-68, Technetium-99m, Lutetium-177, Actinium-225 and Others), By Therapeutic Area (Oncology, Neurology, Cardiology and Others), By Application (Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals) and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034

Category: Healthcare Report Format : PDF Pages: 228 Report Code: ZMR-10588 Published Date: May-2026 Status : Published
Market Size in 2024 Market Forecast in 2034 CAGR (in %) Base Year
USD 2.9 Billion USD 7.2 Billion 9.5% 2024

Table Of Content

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Radiopharmaceutical CDMO Market, (2025 - 2034) (USD Billion)
    • 2.2 Global Radiopharmaceutical CDMO Market : snapshot
  • Chapter 3. Global Radiopharmaceutical CDMO Market - Industry Analysis
    • 3.1 Radiopharmaceutical CDMO Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 The rising demand for precision oncology drive the Radiopharmaceutical CDMO market
    • 3.3 Market Restraints
      • 3.3.1. The high capital investment requirements hinder the growth of the Radiopharmaceutical CDMO industry
    • 3.4 Market Opportunities
      • 3.4.1. The rising expansion activities of key market players create a lucrative opportunity for the Radiopharmaceutical CDMO market
    • 3.5 Market Challenges
      • 3.5.1. Limited skilled workforce poses a significant challenge to the Radiopharmaceutical CDMO market?
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Service Type
      • 3.7.2 Market attractiveness analysis By Radioisotope Type
      • 3.7.3 Market attractiveness analysis By Therapeutic Area
      • 3.7.4 Market attractiveness analysis By Application
  • Chapter 4. Global Radiopharmaceutical CDMO Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Radiopharmaceutical CDMO Market: company market share, 2024
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Radiopharmaceutical CDMO Market - Service Type Analysis
    • 5.1 Global Radiopharmaceutical CDMO Market overview: By Service Type
      • 5.1.1 Global Radiopharmaceutical CDMO Market share, By Service Type, 2024 and 2034
    • 5.2 Contract Manufacturing
      • 5.2.1 Global Radiopharmaceutical CDMO Market by Contract Manufacturing, 2025 - 2034 (USD Billion)
    • 5.3 Analytical & Quality Control Services
      • 5.3.1 Global Radiopharmaceutical CDMO Market by Analytical & Quality Control Services, 2025 - 2034 (USD Billion)
    • 5.4 Contract Development
      • 5.4.1 Global Radiopharmaceutical CDMO Market by Contract Development, 2025 - 2034 (USD Billion)
    • 5.5 Packaging, Labeling & Logistics
      • 5.5.1 Global Radiopharmaceutical CDMO Market by Packaging, Labeling & Logistics, 2025 - 2034 (USD Billion)
  • Chapter 6. Global Radiopharmaceutical CDMO Market - Radioisotope Type Analysis
    • 6.1 Global Radiopharmaceutical CDMO Market overview: By Radioisotope Type
      • 6.1.1 Global Radiopharmaceutical CDMO Market share, By Radioisotope Type, 2024 and 2034
    • 6.2 Fluorine-18
      • 6.2.1 Global Radiopharmaceutical CDMO Market by Fluorine-18, 2025 - 2034 (USD Billion)
    • 6.3 Gallium-68
      • 6.3.1 Global Radiopharmaceutical CDMO Market by Gallium-68, 2025 - 2034 (USD Billion)
    • 6.4 Technetium-99m
      • 6.4.1 Global Radiopharmaceutical CDMO Market by Technetium-99m, 2025 - 2034 (USD Billion)
    • 6.5 Lutetium-177
      • 6.5.1 Global Radiopharmaceutical CDMO Market by Lutetium-177, 2025 - 2034 (USD Billion)
    • 6.6 Actinium-225
      • 6.6.1 Global Radiopharmaceutical CDMO Market by Actinium-225, 2025 - 2034 (USD Billion)
    • 6.7 Others
      • 6.7.1 Global Radiopharmaceutical CDMO Market by Others, 2025 - 2034 (USD Billion)
  • Chapter 7. Global Radiopharmaceutical CDMO Market - Therapeutic Area Analysis
    • 7.1 Global Radiopharmaceutical CDMO Market overview: By Therapeutic Area
      • 7.1.1 Global Radiopharmaceutical CDMO Market share, By Therapeutic Area, 2024 and 2034
    • 7.2 Oncology
      • 7.2.1 Global Radiopharmaceutical CDMO Market by Oncology, 2025 - 2034 (USD Billion)
    • 7.3 Neurology
      • 7.3.1 Global Radiopharmaceutical CDMO Market by Neurology, 2025 - 2034 (USD Billion)
    • 7.4 Cardiology
      • 7.4.1 Global Radiopharmaceutical CDMO Market by Cardiology, 2025 - 2034 (USD Billion)
    • 7.5 Others
      • 7.5.1 Global Radiopharmaceutical CDMO Market by Others, 2025 - 2034 (USD Billion)
  • Chapter 8. Global Radiopharmaceutical CDMO Market - Application Analysis
    • 8.1 Global Radiopharmaceutical CDMO Market overview: By Application
      • 8.1.1 Global Radiopharmaceutical CDMO Market share, By Application, 2024 and 2034
    • 8.2 Diagnostic Radiopharmaceuticals
      • 8.2.1 Global Radiopharmaceutical CDMO Market by Diagnostic Radiopharmaceuticals, 2025 - 2034 (USD Billion)
    • 8.3 Therapeutic Radiopharmaceuticals
      • 8.3.1 Global Radiopharmaceutical CDMO Market by Therapeutic Radiopharmaceuticals, 2025 - 2034 (USD Billion)
  • Chapter 9. Radiopharmaceutical CDMO Market - Regional Analysis
    • 9.1 Global Radiopharmaceutical CDMO Market Regional Overview
    • 9.2 Global Radiopharmaceutical CDMO Market Share, by Region, 2024 & 2034 (USD Billion)
    • 9.3. North America
      • 9.3.1 North America Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
        • 9.3.1.1 North America Radiopharmaceutical CDMO Market, by Country, 2025 - 2034 (USD Billion)
    • 9.4 North America Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034
      • 9.4.1 North America Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034 (USD Billion)
    • 9.5 North America Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034
      • 9.5.1 North America Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034 (USD Billion)
    • 9.6 North America Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034
      • 9.6.1 North America Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034 (USD Billion)
    • 9.7 North America Radiopharmaceutical CDMO Market, by Application, 2025 - 2034
      • 9.7.1 North America Radiopharmaceutical CDMO Market, by Application, 2025 - 2034 (USD Billion)
    • 9.4. Europe
      • 9.4.2 Europe Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
        • 9.4.2.1 Europe Radiopharmaceutical CDMO Market, by Country, 2025 - 2034 (USD Billion)
    • 9.4 Europe Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034
      • 9.4.1 Europe Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034 (USD Billion)
    • 9.5 Europe Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034
      • 9.5.1 Europe Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034 (USD Billion)
    • 9.6 Europe Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034
      • 9.6.1 Europe Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034 (USD Billion)
    • 9.7 Europe Radiopharmaceutical CDMO Market, by Application, 2025 - 2034
      • 9.7.1 Europe Radiopharmaceutical CDMO Market, by Application, 2025 - 2034 (USD Billion)
    • 9.5. Asia Pacific
      • 9.5.3 Asia Pacific Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
        • 9.5.3.1 Asia Pacific Radiopharmaceutical CDMO Market, by Country, 2025 - 2034 (USD Billion)
    • 9.4 Asia Pacific Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034
      • 9.4.1 Asia Pacific Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034 (USD Billion)
    • 9.5 Asia Pacific Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034
      • 9.5.1 Asia Pacific Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034 (USD Billion)
    • 9.6 Asia Pacific Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034
      • 9.6.1 Asia Pacific Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034 (USD Billion)
    • 9.7 Asia Pacific Radiopharmaceutical CDMO Market, by Application, 2025 - 2034
      • 9.7.1 Asia Pacific Radiopharmaceutical CDMO Market, by Application, 2025 - 2034 (USD Billion)
    • 9.6. Latin America
      • 9.6.4 Latin America Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
        • 9.6.4.1 Latin America Radiopharmaceutical CDMO Market, by Country, 2025 - 2034 (USD Billion)
    • 9.4 Latin America Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034
      • 9.4.1 Latin America Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034 (USD Billion)
    • 9.5 Latin America Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034
      • 9.5.1 Latin America Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034 (USD Billion)
    • 9.6 Latin America Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034
      • 9.6.1 Latin America Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034 (USD Billion)
    • 9.7 Latin America Radiopharmaceutical CDMO Market, by Application, 2025 - 2034
      • 9.7.1 Latin America Radiopharmaceutical CDMO Market, by Application, 2025 - 2034 (USD Billion)
    • 9.7. The Middle-East and Africa
      • 9.7.5 The Middle-East and Africa Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
        • 9.7.5.1 The Middle-East and Africa Radiopharmaceutical CDMO Market, by Country, 2025 - 2034 (USD Billion)
    • 9.4 The Middle-East and Africa Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034
      • 9.4.1 The Middle-East and Africa Radiopharmaceutical CDMO Market, by Service Type, 2025 - 2034 (USD Billion)
    • 9.5 The Middle-East and Africa Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034
      • 9.5.1 The Middle-East and Africa Radiopharmaceutical CDMO Market, by Radioisotope Type, 2025 - 2034 (USD Billion)
    • 9.6 The Middle-East and Africa Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034
      • 9.6.1 The Middle-East and Africa Radiopharmaceutical CDMO Market, by Therapeutic Area, 2025 - 2034 (USD Billion)
    • 9.7 The Middle-East and Africa Radiopharmaceutical CDMO Market, by Application, 2025 - 2034
      • 9.7.1 The Middle-East and Africa Radiopharmaceutical CDMO Market, by Application, 2025 - 2034 (USD Billion)
  • Chapter 10. Company Profiles
    • 10.1 ABX advanced biochemical compounds
      • 10.1.1 Overview
      • 10.1.2 Financials
      • 10.1.3 Product Portfolio
      • 10.1.4 Business Strategy
      • 10.1.5 Recent Developments
    • 10.2 Cardinal Health Nuclear & Precision Health Solutions
      • 10.2.1 Overview
      • 10.2.2 Financials
      • 10.2.3 Product Portfolio
      • 10.2.4 Business Strategy
      • 10.2.5 Recent Developments
    • 10.3 AtomVie Global Radiopharma
      • 10.3.1 Overview
      • 10.3.2 Financials
      • 10.3.3 Product Portfolio
      • 10.3.4 Business Strategy
      • 10.3.5 Recent Developments
    • 10.4 Cyclotek
      • 10.4.1 Overview
      • 10.4.2 Financials
      • 10.4.3 Product Portfolio
      • 10.4.4 Business Strategy
      • 10.4.5 Recent Developments
    • 10.5 Curium
      • 10.5.1 Overview
      • 10.5.2 Financials
      • 10.5.3 Product Portfolio
      • 10.5.4 Business Strategy
      • 10.5.5 Recent Developments
    • 10.6 Eckert & Ziegler Radiopharma
      • 10.6.1 Overview
      • 10.6.2 Financials
      • 10.6.3 Product Portfolio
      • 10.6.4 Business Strategy
      • 10.6.5 Recent Developments
    • 10.7 Evergreen Theragnostics
      • 10.7.1 Overview
      • 10.7.2 Financials
      • 10.7.3 Product Portfolio
      • 10.7.4 Business Strategy
      • 10.7.5 Recent Developments
    • 10.8 Isotopia Molecular Imaging
      • 10.8.1 Overview
      • 10.8.2 Financials
      • 10.8.3 Product Portfolio
      • 10.8.4 Business Strategy
      • 10.8.5 Recent Developments
    • 10.9 ITM Isotope Technologies Munich
      • 10.9.1 Overview
      • 10.9.2 Financials
      • 10.9.3 Product Portfolio
      • 10.9.4 Business Strategy
      • 10.9.5 Recent Developments
    • 10.10 Jubilant Radiopharma
      • 10.10.1 Overview
      • 10.10.2 Financials
      • 10.10.3 Product Portfolio
      • 10.10.4 Business Strategy
      • 10.10.5 Recent Developments
    • 10.11 Nihon Medi-Physics
      • 10.11.1 Overview
      • 10.11.2 Financials
      • 10.11.3 Product Portfolio
      • 10.11.4 Business Strategy
      • 10.11.5 Recent Developments
    • 10.12 Minerva Imaging
      • 10.12.1 Overview
      • 10.12.2 Financials
      • 10.12.3 Product Portfolio
      • 10.12.4 Business Strategy
      • 10.12.5 Recent Developments
    • 10.13 NorthStar Medical Radioisotopes
      • 10.13.1 Overview
      • 10.13.2 Financials
      • 10.13.3 Product Portfolio
      • 10.13.4 Business Strategy
      • 10.13.5 Recent Developments
    • 10.14 Nucleus RadioPharma
      • 10.14.1 Overview
      • 10.14.2 Financials
      • 10.14.3 Product Portfolio
      • 10.14.4 Business Strategy
      • 10.14.5 Recent Developments
    • 10.15 Monrol
      • 10.15.1 Overview
      • 10.15.2 Financials
      • 10.15.3 Product Portfolio
      • 10.15.4 Business Strategy
      • 10.15.5 Recent Developments
    • 10.16 SpectronRx
      • 10.16.1 Overview
      • 10.16.2 Financials
      • 10.16.3 Product Portfolio
      • 10.16.4 Business Strategy
      • 10.16.5 Recent Developments
    • 10.17 PharmaLogic
      • 10.17.1 Overview
      • 10.17.2 Financials
      • 10.17.3 Product Portfolio
      • 10.17.4 Business Strategy
      • 10.17.5 Recent Developments
    • 10.18 SOFIE and Siemens Healthineers PETNET Solutions
      • 10.18.1 Overview
      • 10.18.2 Financials
      • 10.18.3 Product Portfolio
      • 10.18.4 Business Strategy
      • 10.18.5 Recent Developments
    • 10.19 and others.
      • 10.19.1 Overview
      • 10.19.2 Financials
      • 10.19.3 Product Portfolio
      • 10.19.4 Business Strategy
      • 10.19.5 Recent Developments

Table Of Figures

  • 1. Market research Type
  • 2. Market research methodology
  • 3. Global Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
  • 4. Porter’s Five Forces Analysis
  • 5. Global Radiopharmaceutical CDMO Market attractiveness, By Service Type
  • 6. Global Radiopharmaceutical CDMO Market attractiveness, By Radioisotope Type
  • 7. Global Radiopharmaceutical CDMO Market attractiveness, By Therapeutic Area
  • 8. Global Radiopharmaceutical CDMO Market attractiveness, By Application
  • 9. Global Radiopharmaceutical CDMO Market share by Service Type, 2025 and 2034 (USD Billion)
  • 10. Global Radiopharmaceutical CDMO Market by Contract Manufacturing, 2025 - 2034 (USD Billion)
  • 11. Global Radiopharmaceutical CDMO Market by Analytical & Quality Control Services, 2025 - 2034 (USD Billion)
  • 12. Global Radiopharmaceutical CDMO Market by Contract Development, 2025 - 2034 (USD Billion)
  • 13. Global Radiopharmaceutical CDMO Market by Packaging, Labeling & Logistics, 2025 - 2034 (USD Billion)
  • 14. Global Radiopharmaceutical CDMO Market share by Radioisotope Type, 2025 and 2034 (USD Billion)
  • 15. Global Radiopharmaceutical CDMO Market by Fluorine-18, 2025 - 2034 (USD Billion)
  • 16. Global Radiopharmaceutical CDMO Market by Gallium-68, 2025 - 2034 (USD Billion)
  • 17. Global Radiopharmaceutical CDMO Market by Technetium-99m, 2025 - 2034 (USD Billion)
  • 18. Global Radiopharmaceutical CDMO Market by Lutetium-177, 2025 - 2034 (USD Billion)
  • 19. Global Radiopharmaceutical CDMO Market by Actinium-225, 2025 - 2034 (USD Billion)
  • 20. Global Radiopharmaceutical CDMO Market by Others, 2025 - 2034 (USD Billion)
  • 21. Global Radiopharmaceutical CDMO Market share by Therapeutic Area, 2025 and 2034 (USD Billion)
  • 22. Global Radiopharmaceutical CDMO Market by Oncology, 2025 - 2034 (USD Billion)
  • 23. Global Radiopharmaceutical CDMO Market by Neurology, 2025 - 2034 (USD Billion)
  • 24. Global Radiopharmaceutical CDMO Market by Cardiology, 2025 - 2034 (USD Billion)
  • 25. Global Radiopharmaceutical CDMO Market by Others, 2025 - 2034 (USD Billion)
  • 26. Global Radiopharmaceutical CDMO Market share by Application, 2025 and 2034 (USD Billion)
  • 27. Global Radiopharmaceutical CDMO Market by Diagnostic Radiopharmaceuticals, 2025 - 2034 (USD Billion)
  • 28. Global Radiopharmaceutical CDMO Market by Therapeutic Radiopharmaceuticals, 2025 - 2034 (USD Billion)
  • 29. Global Radiopharmaceutical CDMO Market share, by Region, 2025 and 2034
  • 30. North America Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
  • 31. Europe Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
  • 32. Asia Pacific Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
  • 33. Latin America Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)
  • 34. The Middle-East and Africa Radiopharmaceutical CDMO Market, 2025 - 2034 (USD Billion)

Table Of Tables

  • 1. Global Radiopharmaceutical CDMO Market: Snapshot
  • 2. Drivers of the Radiopharmaceutical CDMO Market: impact analysis
  • 3. North America Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 4. North America Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 5. North America Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 6. North America Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 7. U.S. Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 8. U.S. Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 9. U.S. Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 10. U.S. Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 11. Canada Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 12. Canada Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 13. Canada Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 14. Canada Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 15. Europe Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 16. Europe Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 17. Europe Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 18. Europe Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 19. Germany Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 20. Germany Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 21. Germany Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 22. Germany Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 23. France Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 24. France Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 25. France Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 26. France Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 27. U.K. Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 28. U.K. Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 29. U.K. Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 30. U.K. Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 31. Italy Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 32. Italy Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 33. Italy Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 34. Italy Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 35. Spain Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 36. Spain Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 37. Spain Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 38. Spain Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 39. Rest of Europe Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 40. Rest of Europe Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 41. Rest of Europe Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 42. Rest of Europe Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 43. Asia Pacific Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 44. Asia Pacific Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 45. Asia Pacific Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 46. Asia Pacific Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 47. China Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 48. China Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 49. China Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 50. China Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 51. Japan Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 52. Japan Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 53. Japan Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 54. Japan Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 55. India Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 56. India Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 57. India Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 58. India Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 59. South Korea Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 60. South Korea Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 61. South Korea Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 62. South Korea Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 63. South-East Asia Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 64. South-East Asia Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 65. South-East Asia Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 66. South-East Asia Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 67. Rest of Asia Pacific Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 68. Rest of Asia Pacific Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 69. Rest of Asia Pacific Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 70. Rest of Asia Pacific Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 71. Latin America Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 72. Latin America Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 73. Latin America Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 74. Latin America Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 75. Brazil Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 76. Brazil Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 77. Brazil Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 78. Brazil Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 79. Mexico Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 80. Mexico Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 81. Mexico Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 82. Mexico Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 83. Rest of Latin America Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 84. Rest of Latin America Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 85. Rest of Latin America Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 86. Rest of Latin America Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 87. The Middle-East and Africa Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 88. The Middle-East and Africa Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 89. The Middle-East and Africa Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 90. The Middle-East and Africa Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 91. GCC Countries Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 92. GCC Countries Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 93. GCC Countries Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 94. GCC Countries Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 95. South Africa Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 96. South Africa Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 97. South Africa Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 98. South Africa Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)
  • 99. Rest of Middle-East Africa Radiopharmaceutical CDMO Market revenue, By Service Type, 2025 - 2034 (USD Billion)
  • 100. Rest of Middle-East Africa Radiopharmaceutical CDMO Market revenue, By Radioisotope Type, 2025 - 2034 (USD Billion)
  • 101. Rest of Middle-East Africa Radiopharmaceutical CDMO Market revenue, By Therapeutic Area, 2025 - 2034 (USD Billion)
  • 102. Rest of Middle-East Africa Radiopharmaceutical CDMO Market revenue, By Application, 2025 - 2034 (USD Billion)

Methodology

FrequentlyAsked Questions

The radiopharmaceutical CDMO market is an industry comprising third parties that provide services, including research and development, manufacturing, packaging, testing, and distribution of radiopharmaceutical drugs used in nuclear medicine.

The key growth drivers for the Radiopharmaceutical CDMO market include rising demand for precision oncology and theranostics, increasing adoption of PET and SPECT imaging, expanding radioligand therapy pipelines, growing outsourcing by pharmaceutical companies, advancements in isotope production technologies, and increasing investments in nuclear medicine infrastructure.

The major challenges restraining the growth of the Radiopharmaceutical CDMO market include high capital investment requirements, limited availability of critical radioisotopes, complex regulatory compliance, short isotope half-lives, radiation safety concerns, shortage of skilled professionals, high operational costs, and logistical challenges associated with time-sensitive transportation and cold-chain distribution.

Based on the application, the diagnostic radiopharmaceuticals segment is expected to dominate the Radiopharmaceutical CDMO market growth during the projected period.

Emerging trends and innovations impacting the Radiopharmaceutical CDMO market include the expansion of theranostics and radioligand therapies, advancements in cyclotron and isotope production technologies, increasing use of AI-driven radiopharmaceutical development, growth of Actinium-225 and Lutetium-177 therapies, automation in radiochemistry manufacturing, and rising investments in decentralized nuclear medicine production facilities.

According to the report, the global Radiopharmaceutical CDMO market size was worth around USD 2.9 billion in 2024 and is predicted to grow to around USD 7.2 billion by 2034.

The global Radiopharmaceutical CDMO market is expected to grow at a CAGR of 9.5% during the forecast period.

The global Radiopharmaceutical CDMO industry growth is expected to be led by North America over the forecast period.

The global Radiopharmaceutical CDMO market is dominated by players like ABX advanced biochemical compounds, Cardinal Health Nuclear & Precision Health Solutions, AtomVie Global Radiopharma, Cyclotek, Curium, Eckert & Ziegler Radiopharma, Evergreen Theragnostics, Isotopia Molecular Imaging, ITM Isotope Technologies Munich, Jubilant Radiopharma, Nihon Medi-Physics, Minerva Imaging, NorthStar Medical Radioisotopes, Nucleus RadioPharma, Monrol, SpectronRx, PharmaLogic, SOFIE and Siemens Healthineers PETNET Solutions among others.

The market report covers the geographical market along with a comprehensive competitive landscape analysis. It also includes cash flow analysis, profit ratio analysis, market basket analysis, market attractiveness analysis, sentiment analysis, PESTLE analysis, trend analysis, SWOT analysis, trade area analysis, demand & supply analysis, Porter’s five forces analysis, and value chain analysis.

  • zion payment modes

List of Contents

Radiopharmaceutical CDMOIndustry Perspective:Key InsightsOverviewDynamicsReport ScopeSegmentationCompetitive AnalysisThe global market is segmented as follows:

HappyClients